2.2 Potential drug candidates in clinical trials
Remdesivir (GS-5734) is an adenosine analogue that has completed the
phase III clinical trial for the treatment of Ebola virus infection. The
antiviral drug remdesivir (GS-5734) is entered to the phase III clinical
trials in Asian countries to assess the use of antiviral drug candidate
for the potential treatment of coronavirus by Gilead Sciences. All
reported potential drug candidates in clinical trials and their status
are presented in Table 2. Moreover, multiple parallel attempts are in
progress to develop 2019-nCoV vaccine. Currently 18 vaccine candidates
are in preclinical phases and five candidates are in clinical phases
(Table 3).